{"name":"Eilean Therapeutics","slug":"eilean-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOdkJBM0w4TUUxY2d1Sm1pTWtIWC1jeTc5M1l1Um9PejR0ZTBGNUV1Y0drM1Vzbl92RTM1QnJiVFJiZEpBTjBVWDhIaTVDamZvNTE3UDZVR1Q2b21iQTkxQ3l1VU0xX2swSzR4TXlFOUVkaUpFUlpGSHZzU2sySEN3Rml4SWpvdVh3ckJZdGk0U1lVaXg1U3FJ?oc=5","date":"2025-12-22","type":"pipeline","source":"BioWorld News","summary":"Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld News","headline":"Mondego Bio selects ZE00-0388 as clinical candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPNVhiVEVObkVfb1ZoQkZrdlU5alQ3SmhJLTRDT1J3ZFNyMk5QcnF0bDh2aWFta01ZX3g5b1htd2t2QWtVbktBOEtnbXo5Y1VvdUJDTFFSdDNZcGFRbkRkQ3lhVHJmbWxabFlNTmdOUll4SFNtdjZtZ3p1V0dWU2R5UzBPQmFfOHE4MXRTTGYyVkU2V0RIekdZcnJhQU1fMkNYbVN3RXVIMWl0SVpaM014M2RTb19iZUZxdnlydVRyRFJUZC1MaDVEWVc0RE1TUmFMRDV2WGZLM1I1c2hiT3FRSEt1djdGdDhTeTV5YjFaWDVWUG81cnNBRTh0dFFFcTBtZzZOLTRGcTlIaHcwYlM3WUEtMUw?oc=5","date":"2025-12-17","type":"pipeline","source":"PR Newswire","summary":"Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development - PR Newswire","headline":"Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxNd19melVxa0FORVc5U2pYVGlabnZwVk1YTnpOZzJ4R3RESmFHR21fYjBfRE54Uk1pVl9nWmo0UnZNRTRVaWRQQ3JTR3oyUVZXYllCaXo2WHI1eE9JVlUyLWJpVW1GWjFjdHl5U1lEQjF6SThfb05iU0ZkdUQxOTQxWTM5OXJaMllZNnF3M1d0SHBzUm9xaEl4MnVaTV9wNExwamdFTW9XT1FQckpmNnpwR2RpbThxSHBYd0F2N05CcVlCam45VXp5dGRQSGVZTmJ5bWZCQkZnWUl3c29YU3FoLUVMMnJqWnJQUHYwX1paeFpqSGVoeENlckZlQmF2bm56b3NOWjU2aDZwNjAwbTU0d3hqUjFhMndfVGdIbUlsQXUzMTRPQWdlclVPTFpKaXozcDJ4ejV3?oc=5","date":"2025-11-06","type":"pipeline","source":"PR Newswire","summary":"Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025 - PR Newswire","headline":"Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Init","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxQNk4ybW5hcE5QeHFJY0psWE1uVXh4RGxSb09QTkdrUEo5czFER19zSmFqaUMyNExKaml5M3htMWRHR2JuZ3d6NlFUQm5FbHktdll3ckJ4bEdwaFBzMjh4NURaY0Q1UFdfaEVJZ29IT2cwQXB2UnY1UnJwQ1NWaW1sTzlMQ1BJY2pFTzNtT0JpTU5hTmxSMUpPeVZ5QTNfVHhWVGhKMmI1d1gzakh4VjFXMFo5TUhZWG1aRWNRREJ3NlotSnZ5QW9GSmdieTJIMnBEWWVPS21nZmU2WWNhY0hoVnhZa05ROXBKdFJvb05YcnJaNzFmRzFtYjV6X2l5ZWxKXzU3WkNJUnR3dU0tT0JxOC1BR1ZfU1A5ZDNZd0tMYUl2ZTVFS0RJVGt5elRqM1E2MUxwbDhIUkYzcUJLZW1hNGtFYjVIdTh3b3dSWnhqWGRIejc1ZkotdjFLWmg?oc=5","date":"2025-11-04","type":"pipeline","source":"PR Newswire","summary":"Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology - PR Newswire","headline":"Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQRlZkdHN3eTFjc0I1UmxDaG9VWWMwWGFubjZqbGYtRFhDUXNrM3pEODY1XzE4eVlkdW5SRldQTWMtNExoUUhuZ3RJZFkxN2xPSUFld1o1Y1hYY0JTLXNDVk1YRkU0N0IxQ1NhX21OVzBuVWFYekJQUGN1d0pNbkhzQ0p5LUVibjNJMGlNUkc4MUZaWkVKQk5mSldn?oc=5","date":"2025-10-16","type":"pipeline","source":"Yahoo Finance","summary":"Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight - Yahoo Finance","headline":"Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNSHhTTlNxd2J3ZnFTX0ZpdEpubTFmSnJBT0ZMZkhnTXNCMk1BbHRoUEctNGN6d0ZBd3NVZUVTZ3BKT21tZ1MwTlZ1MnpWRU9UamRmVE90YkVCM1hweXVzd1VyMnFZTkR1aXZ0WmplbGFQTW9UTzFPUUZnUWlhZWNHSElDLUpITzRuYjVqSHpDNTR2dzAwcWZsT1dZSDZHbFJsYWctUTVya010Vjl1Q0s3bm5JZWhEZ2g1cndIMU5ycnRielBaYUhteDhmZTJnOTVDS0cwa19Pc010MC1pa094UDVQcVJMMTE0STE1ajV0MUQzTWVmWTR6aTVQR0plSUh3T0E?oc=5","date":"2025-10-16","type":"pipeline","source":"PR Newswire","summary":"Eilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent Cancers - PR Newswire","headline":"Eilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent Cancers","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-13","type":"pipeline","source":"PR Newswire","summary":"EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Co","headline":"EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Agai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOQTFEOTRDWVJ2YmlldTMyZnc4SFBrN0RYc19idzM3YXBSVlBVSEFKV3NKZU14SVJac0NnVjluMks5WGFyaTR4cEoxYXU1eUtDc0JRcTQwOEdfZURkUkFKVXM2RXRXWnpxZ21Qb0VnZEFIYUtleE1GdGNwTTRKX3ljMFpBSW5BWjdHVUV3UDRMM3lzbGdULUtRSDhwUWkwQnlpVnJMYUZiNmh2ZGFWV3RIeg?oc=5","date":"2024-12-10","type":"pipeline","source":"University of Cincinnati","summary":"AML, sickle cell disease research among highlights of ASH abstracts - University of Cincinnati","headline":"AML, sickle cell disease research among highlights of ASH abstracts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxOampWb3JUOGt1N1R2b2J2bkJJY0Itemt0a0o3bUJWdXhtX0YwZEl5M0toWTV6cjBtTFlKUlhBSGRRa182R1dLV3ZqeFlSMERaSGx5LVpZTXFSdGVjZ2hheDRwMW0yaGVpMkV2VUk0dDRMcVdwMTNoVGVqbG85TlVMbXhsOFAzaVh2SjItMUM1M0RlNW53bmdrMTFicUtfdTRXWmYyNmRNamhfMVVGVTQ0N2FBN0tuQ2hhTl9iVnliUTgzQ0RfS2lYekNVRWlNdEw2c2RFQU5GNEREaG9kSW84bHVzck1yS2FrWWgwZm5KcF9IdExpLWIyODVVQWdFLUg3bkJ3V1ptVG9qREJ0VGN0UnJKRTdjazZxNUlmQWk3ajN5eVA3bGFBZ28tUXFobGYw?oc=5","date":"2024-06-10","type":"regulatory","source":"PR Newswire","summary":"Eilean Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lomonitinib for the Treatment of Acute Myeloid Leukemia (AML) - PR Newswire","headline":"Eilean Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lomonitinib for the Treatm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBpZ0ZEZW1JazJ0bnpIc1c2d1RzTExXM1RKaXRJSFdac0NGbW54ZjdoUy12VzV0aTN1N0ctNUpwRTMta2hwV3JYNkQxUDFLNWYzLU5PcGFIN2tOLVMtZTRpWkdTcGxhcGlsVU1PWVNuVzRINVBxMDVn?oc=5","date":"2024-04-05","type":"regulatory","source":"Clinical Trials Arena","summary":"Eilean receives Australian HREC approval to begin Phase I AML trial - Clinical Trials Arena","headline":"Eilean receives Australian HREC approval to begin Phase I AML trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNQy1QZE5vVHRaTEhZWFNETXNjRWV2UG9jdFNTaDlZcl9OWjZmazEtZFBTMUhfZkN6ZnZ1VmRjdElqT2JGbkthbk9VNUJBS1V1THB5OW44Qzk5SUFZRzQzbVU0RTkxN0pKd1V0NWNfUHpLdllmSkNvbmNfZ1J5U1JlMng1bV9mMTQwZV9aTVlDYXlvNFJsazBNZGthVFhWQU5IM21BN09iODBmNTh5YzZwaG1hMXl5RE1uUzJCX1dVLTcySkRYbWkwMktpVFJxNWZyLXliNEtUdlFJdEpiNlJKb2JhV19GcjQ?oc=5","date":"2024-03-11","type":"regulatory","source":"BioSpace","summary":"EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR - BioSpace","headline":"EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPU3pZSHZGWHN3MXFvNmM2bnNWeG9NMjZkdnR6TFZxSVBIVC03eDZjMUVoZE85UU5IWjZROHBDWEYtdDhvaURpeElSMVZfcTFHZWpqSWwxQU1wZWlTdGs0T2RoVThlRVhXZ2s1Ukh2TkJvRjZzVGtlalh4VUVkb1M5NjB2VVFxVFpNVVB4MmxsQ2RvZUVpWGJR?oc=5","date":"2024-03-04","type":"deal","source":"Contract Pharma","summary":"Eilean Therapeutics Acquires Ness Therapeutics - Contract Pharma","headline":"Eilean Therapeutics Acquires Ness Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}